Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Acronyms KODIAC-07
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Jun 2016 Results of pooled analysis of three phase III studies (KODIAC 4, KODIAC 5 and KODIAC 7) published in the Advances in Therapy
    • 16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.
    • 10 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top